CLINICAL TRIALS PROFILE FOR CLOTRIMAZOLE

505(b)(2) Clinical Trials for CLOTRIMAZOLE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT03115073 ↗	ProF-001_Phase IIa	Completed	ProFem GmbH	Phase 2/Phase 3	2017-04-04	This is a multi-center, randomized, prospective, active-controlled, double-blind, dose-escalation study comparing dose response of clinical efficacy, safety, local tolerability of three different doses of ProF-001/Candiplus® (Candiplus® 0.2%, Candiplus® with 0.3%, Candiplus® with 0.4%) to 1% clotrimazole vaginal cream. Patients with acute episode of vulvovaginal candidiasis (VVC) will be randomized to receive a daily dose of either 5 ml (intravaginal) of Candiplus® at three different doses for the first 3 days and 2.5 ml for the remaining 3 days or 5 ml (intravaginal) application of 1% clotrimazole cream over the first 3 days and 2.5 ml for the remaining 3 days according to the following scheme (with each application 2 cm of cream will be applied to the vulvar region): Cohort 1: Candiplus® 0.2% versus clotrimazole mono Cohort 2: Candiplus® 0.3% versus clotrimazole mono Cohort 3: Candiplus® 0.4% versus clotrimazole mono Randomization into the cohorts will occur consecutively from the lowest dose to the highest dose, i.e. patients will be randomized first in cohort 1 and finally in cohort 3. The proposed study is - after a pilot study to assess critical pharmacokinetic data - the second study within a clinical trial program with the objective to develop a new combination therapy for the treatment of vulvovaginal candidiasis. The new combination consists of two registered drug substances.

All Clinical Trials for CLOTRIMAZOLE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000676 ↗	Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)	Completed	Pfizer	Phase 3	1969-12-31	To study the effectiveness, safety, and tolerance of fluconazole versus clotrimazole troches (lozenges) as prophylaxis (preventive treatment) against fungal infections in patients enrolled in ACTG 081 (a study of prophylaxis against pneumocystosis, toxoplasmosis, and serious bacterial infection). Primarily, to compare the rates of invasive infections by C. neoformans, endemic mycoses, and Candida. To compare the mortality rates due to fungal infections between two antifungal prophylactic treatments. Secondarily, to assess the effect of prophylaxis on the incidence of severe fungal infections, defined as invasive infections and esophageal candidiasis and less severe mucocutaneous infection. Serious fungal infections are significant complicating and life-threatening occurrences in patients with advanced HIV infection. Oropharyngeal candidiasis is found in almost all such patients, and causes pain, difficulty in swallowing, and loss of appetite. Similarly, esophageal candidiasis causes illness in the population. Cryptococcosis, endemic mycoses, and coccidioidomycosis also cause significant illness and death in AIDS patients. Once established, fungal infections in AIDS patients generally require continuous suppressive therapy because attempts at curing these infections are usually unsuccessful. Fluconazole has a number of characteristics that would make it a logical candidate to examine as a prophylactic agent in patients with advanced HIV infection. Animal studies have shown it to be prophylactic in models of candidiasis, cryptococcosis, histoplasmosis, and coccidioidomycosis. Initial experience in patients with active cryptococcal meningitis appears favorable, and studies of oropharyngeal candidiasis show it to be effective.
NCT00000676 ↗	Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To study the effectiveness, safety, and tolerance of fluconazole versus clotrimazole troches (lozenges) as prophylaxis (preventive treatment) against fungal infections in patients enrolled in ACTG 081 (a study of prophylaxis against pneumocystosis, toxoplasmosis, and serious bacterial infection). Primarily, to compare the rates of invasive infections by C. neoformans, endemic mycoses, and Candida. To compare the mortality rates due to fungal infections between two antifungal prophylactic treatments. Secondarily, to assess the effect of prophylaxis on the incidence of severe fungal infections, defined as invasive infections and esophageal candidiasis and less severe mucocutaneous infection. Serious fungal infections are significant complicating and life-threatening occurrences in patients with advanced HIV infection. Oropharyngeal candidiasis is found in almost all such patients, and causes pain, difficulty in swallowing, and loss of appetite. Similarly, esophageal candidiasis causes illness in the population. Cryptococcosis, endemic mycoses, and coccidioidomycosis also cause significant illness and death in AIDS patients. Once established, fungal infections in AIDS patients generally require continuous suppressive therapy because attempts at curing these infections are usually unsuccessful. Fluconazole has a number of characteristics that would make it a logical candidate to examine as a prophylactic agent in patients with advanced HIV infection. Animal studies have shown it to be prophylactic in models of candidiasis, cryptococcosis, histoplasmosis, and coccidioidomycosis. Initial experience in patients with active cryptococcal meningitis appears favorable, and studies of oropharyngeal candidiasis show it to be effective.
NCT00000991 ↗	A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with HIV infection and T4 cell count less than 200 cells/mm3. All persons completing at least 8 weeks of therapy on 081 will be offered the opportunity to participate in the nested study (ACTG 981) of systemic antifungal therapy (fluconazole) versus local therapy (Clotrimazole) for the prevention of serious fungal disease. Persons with HIV disease who are receiving AZT are at risk for PCP, toxoplasmosis, bacterial pneumonia, and other serious infections. It is therefore important to find drugs that can be given along with AZT to control these infections. Aerosolized pentamidine (PEN) has been shown to be useful in preventing PCP and is expected to lower the 2-year risk of PCP. Both sulfamethoxazole/trimethoprim (SMX/TMP) and dapsone probably also provide effective preventive treatment against PCP, and both may be useful in preventing toxoplasmosis and extrapulmonary pneumocystosis.
NCT00002282 ↗	A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS	Completed	Pfizer	N/A	1969-12-31	To compare the efficacy, safety, and tolerance of fluconazole single daily capsule for 14 days versus clotrimazole troche 5 x daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS.
NCT00004404 ↗	Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes	Completed	Boston Children's Hospital	N/A	1997-04-01	OBJECTIVES: Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes.
NCT00004404 ↗	Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes	Completed	Boston Children’s Hospital	N/A	1997-04-01	OBJECTIVES: Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes.

Clinical Trial Conditions for CLOTRIMAZOLE

Condition Name

Condition Name for CLOTRIMAZOLE
Intervention	Trials
HIV Infections	4
Vulvovaginal Candidiasis	4
Otomycosis	4
Candidiasis	3

Condition MeSH

Condition MeSH for CLOTRIMAZOLE
Intervention	Trials
Candidiasis	16
Candidiasis, Vulvovaginal	10
Infections	6
Infection	6

Clinical Trial Locations for CLOTRIMAZOLE

Trials by Country

Trials by Country for CLOTRIMAZOLE
Location	Trials
United States	61
Brazil	7
Germany	6
Canada	4
India	4

Trials by US State

Trials by US State for CLOTRIMAZOLE
Location	Trials
Massachusetts	5
Pennsylvania	5
New York	5
Maryland	4
California	4

Clinical Trial Progress for CLOTRIMAZOLE

Clinical Trial Phase

Clinical Trial Phase for CLOTRIMAZOLE
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
PHASE1	2

Clinical Trial Status

Clinical Trial Status for CLOTRIMAZOLE
Clinical Trial Phase	Trials
Completed	23
Unknown status	5
Recruiting	3

Clinical Trial Sponsors for CLOTRIMAZOLE

Sponsor Name

Sponsor Name for CLOTRIMAZOLE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	3
Pfizer	2
Peking University Shenzhen Hospital	2

Sponsor Type

Sponsor Type for CLOTRIMAZOLE
Sponsor	Trials
Other	28
Industry	20
NIH	4

Clotrimazole: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 25, 2026

What is clotrimazole and where is it used clinically?

Clotrimazole is an imidazole antifungal used to treat superficial fungal infections. Commercial formulations include topical creams, gels, powders, and pessaries/tablets for genital candidiasis, with additional forms used across dermatology and gynecology. The molecule is widely marketed as an off-patent active ingredient in many jurisdictions, which shapes both clinical-trial activity and market structure (generics, line extensions, and formulation competition rather than new molecular-entity (NME) development).

What does the clinical-trials landscape look like right now?

Clotrimazole’s current clinical-trial footprint is dominated by:

• Bioequivalence studies for generic topical or intravaginal products
• Formulation and dose-form studies (vehicle, particle size, or combination products)
• Special-population or comparator trials that support local regulatory approvals

A large portion of clinical evidence for clotrimazole predates modern trial registries and is not “new” in the sense of first-in-class efficacy claims. Recent registered activity typically does not attempt to establish novel mechanisms; it supports regulatory maintenance for existing therapeutic use patterns and product categories.

What is the practical update for trial activity (phase and volume)?

Public registry visibility for clotrimazole tends to be fragmented and product-specific. Where recent entries exist, they are commonly tagged as:

• Phase 1/2 (often BE or small comparative studies)
• Phase 3 less frequently, because clinical benefit is already established and most current entrants focus on regulatory parity and local label updates

The business implication is direct: trial execution risk is lower than for NMEs, but competitive differentiation hinges on formulation strategy, dosing convenience, and market access rather than new clinical endpoints.

Where do the main regulatory and evidence efforts concentrate?

Across product approvals, the regulatory work for clotrimazole typically concentrates on:

• Demonstrating equivalent antifungal effect to marketed standards through clinical or bridging evidence
• Achieving consistent drug delivery from the vehicle (topical permeability, intravaginal release)
• Stability and product performance for shelf-life and switching between strengths and dosage forms

These activities align with a market dominated by generics and locally branded formulations rather than compound-level development.

How does the patent situation affect clinical and commercial strategy?

Clotrimazole is off-patent. That structure shifts competitive strategy toward:

• Low-cost supply
• Formulation differentiation (vehicle engineering, fixed combinations, dosing regimen changes)
• Contract manufacturing scale
• Distribution channel leverage (OTC status and pharmacy reach in many geographies)

This also explains why clinical-trial “updates” typically do not translate into durable brand-driven premium pricing.

What does the market look like today by product type and channel?

Clotrimazole sells across:

• Topicals (dermatology: tinea, candidiasis of skin folds, athlete’s foot in many markets)
• Intravaginal products (vaginal candidiasis)
• OTC and prescription channels depending on country and formulation strength
• Hospital and primary care usage through standardized antifungal therapy guidelines

Market behavior reflects the molecule’s incumbency and genericization: price competition is intense, and growth is more tied to population needs and formulation penetration than to therapeutic expansion.

How is demand distributed across geography?

Demand is strongest where:

• Out-of-pocket pharmacy purchasing or OTC access boosts volume (topical and intravaginal)
• High prevalence of superficial fungal infections drives baseline treatment rates
• Healthcare reimbursement supports recurrent use in routine care

Europe and North America hold steady demand with strong generic penetration; emerging markets can show higher unit volume growth but typically at lower realized pricing.

What are the competitive dynamics?

Clotrimazole competes primarily on:

• Cost per treated episode
• Dosing convenience (length of therapy)
• Product availability (national tender supply chains)
• Formulation experience (tolerability, spreadability, patient preference)

Brand-led differentiation is limited because most competitors are authorized generics or legacy brands sold in new formats.

How do combination products affect the competitive position?

Some markets use fixed combinations where antifungal plus other actives appear in the same product category. These products can slightly alter share by improving perceived symptom coverage and adherence. However, they do not typically change antifungal efficacy fundamentals for clotrimazole itself; they change purchasing behavior.

Market projection: what growth is realistic for an off-patent antifungal?

For an off-patent active ingredient like clotrimazole, the projection is usually dominated by:

• Volume growth tied to population and infection incidence
• Regimen convenience and OTC availability
• Share shifts between incumbents and generics rather than market creation through new clinical benefits

Realized growth is constrained by:

• Margin compression under generic competition
• Substitution to other antifungals with better adherence profiles (depends on local pricing and guidelines)
• Regulatory actions affecting claims and product switching

Three-scenario market projection framework (global, directional)

Because clotrimazole market reporting varies by analyst methodology (topical vs intravaginal inclusion, OTC vs Rx, and whether combination products are counted separately), a practical projection uses directional ranges rather than a single authoritative number.

Scenario	Annual growth drivers	Expected annual growth rate (directional)	What it means commercially
Base case	Population-driven demand, steady regimen use	Low single-digit	Competing on scale, manufacturing cost, and channel access
Upside	Faster OTC penetration, improved adherence formats	Mid single-digit	Share capture via distribution strength and formulation preference
Downside	Aggressive price erosion, substitution to other antifungals	Low single-digit or flat	Narrowing gross margin; consolidation risk for weaker suppliers

This projection logic is consistent with how off-patent dermatology and gynecology antifungals perform across generics-heavy markets.

What is the most likely “product-level” growth battleground?

For clotrimazole, incremental performance and share growth typically concentrate in:

• Intravaginal formats that improve adherence (short-course regimens where available)
• Cream/gel formulations that support patient preference (spreadability, reduced irritation)
• Economy packs and channel-exclusive SKUs
• Competitive tender positioning for institutional supply (where applicable)

In practical terms, the next meaningful share shifts usually come from commercial execution rather than new clinical endpoints.

Clinical trial strategy implications for R&D and investment

Because clotrimazole’s clinical evidence is mature, new development that attracts capital generally fits one of these patterns:

• Formulation optimization with regulatory-friendly evidence (bioequivalence, bridging endpoints)
• Combination product strategies (if registrable and differentiated by tolerability or adherence)
• Local regulatory and market access programs that convert a generic to a preferred formulary option

Pure “new efficacy” development is unlikely to succeed commercially because clinical benefit is already established and payers and prescribers do not reward incremental claims without meaningful advantage.

Key regulatory and policy anchors affecting market access

Clotrimazole’s market access behavior is shaped by:

• Guideline inclusion for superficial mycoses and vulvovaginal candidiasis
• Switching and substitution rules that favor authorized generics
• OTC classification changes that influence sales velocity

These anchors differ by geography, but the macro effect is consistent: off-patent antifungals sustain volume, while margins stay under pressure.

What diligence points matter most for investors or acquirers?

For a clotrimazole-focused thesis, diligence should prioritize:

1. Manufacturing cost position (API sourcing, yields, downstream process economics)
2. Regulatory portfolio quality (market authorization breadth, renewal track record)
3. Channel concentration (OTC vs institutional tenders vs hospital formularies)
4. SKU economics by dosage form (pricing, rebate pressure, returns risk)
5. Switching risk (presence of competing generics and alternative antifungals with better regimen convenience)

These points determine whether a company can outgrow market volume in a price-competitive category.

---

Key Takeaways

• Clotrimazole remains a mature, off-patent antifungal with clinical evidence rooted in established indications for superficial fungal infections.
• Current “clinical trial updates” are typically formulation- and regulatory-focused (bioequivalence and bridging), not new mechanism or novel efficacy programs.
• Market growth is primarily volume- and access-driven, with low single-digit directional growth in base cases and strong sensitivity to price erosion.
• The main competitive battleground is product form and commercialization execution: OTC penetration, regimen convenience, and tender/channel positioning.
• Investment returns depend more on cost, regulatory coverage, and distribution strength than on R&D novelty.

---

FAQs

1. Is there still meaningful R&D for clotrimazole?
   R&D exists, but it usually centers on formulation development, bioequivalence, and regulatory bridging rather than new clinical breakthroughs.

2. What drives clotrimazole market growth?
   Demand stability plus OTC accessibility and regimen convenience; growth is usually modest and highly sensitive to pricing.

3. Why do trials for clotrimazole look smaller or earlier-phase?
   Because the active ingredient’s efficacy is established, new entrants commonly run BE and small comparative studies to satisfy regulatory requirements.

4. Where can companies differentiate clotrimazole products?
   Vehicle and dosing regimen (cream vs gel vs intravaginal formulations), tolerability profile, and distribution execution.

5. What is the biggest risk in investing in clotrimazole?
   Margin compression from generic competition and faster price erosion than demand growth.

---

References (APA)

[1] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency. (n.d.). EMA: Human medicines. https://www.ema.europa.eu/en/human-medicines
[3] World Health Organization. (n.d.). WHO model lists of essential medicines. https://www.who.int/medicines/publications/essential-medicines-lists/en/